Literature DB >> 18583527

Tumor suppression by p53 in the absence of Atm.

S Lawrence Bailey1, Kay E Gurley, Kyung Hoon-Kim, Karen S Kelly-Spratt, Christopher J Kemp.   

Abstract

Oncogenes can induce p53 through a signaling pathway involving p19/Arf. It was recently proposed that oncogenes can also induce DNA damage, and this can induce p53 through the Atm DNA damage pathway. To assess the relative roles of Atm, Arf, and p53 in the suppression of Ras-driven tumors, we examined susceptibility to skin carcinogenesis in 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Atm- and p53-deficient mice and compared these results to previous studies on Arf-deficient mice. Mice with epidermal-specific deletion of p53 showed increased papilloma number and progression to malignant invasive carcinomas compared with wild-type littermates. In contrast, Atm-deficient mice showed no increase in papilloma number, growth, or malignant progression. gamma-H2AX and p53 levels were increased in both Atm(+/+) and Atm(-/-) papillomas, whereas Arf(-/-) papillomas showed much lower p53 expression. Thus, although there is evidence of DNA damage, signaling through Arf seems to regulate p53 in these Ras-driven tumors. In spontaneous and radiation-induced lymphoma models, tumor latency was accelerated in Atm(-/-)p53(-/-) compound mutant mice compared with the single mutant Atm(-/-) or p53(-/-) mice, indicating cooperation between loss of Atm and loss of p53. Although p53-mediated apoptosis was impaired in irradiated Atm(-/-) lymphocytes, p53 loss was still selected for during lymphomagenesis in Atm(-/-) mice. In conclusion, in these models of oncogene- or DNA damage-induced tumors, p53 retains tumor suppressor activity in the absence of Atm.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18583527      PMCID: PMC2680228          DOI: 10.1158/1541-7786.MCR-07-2009

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  51 in total

1.  ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.

Authors:  Raju V Pusapati; Robert J Rounbehler; SungKi Hong; John T Powers; Mingshan Yan; Kaoru Kiguchi; Mark J McArthur; Paul K Wong; David G Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

2.  Atm is dispensable for p53 apoptosis and tumor suppression triggered by cell cycle dysfunction.

Authors:  M J Liao; C Yin; C Barlow; A Wynshaw-Boris; T van Dyke
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

3.  Critical role for Atm in suppressing V(D)J recombination-driven thymic lymphoma.

Authors:  M J Liao; T Van Dyke
Journal:  Genes Dev       Date:  1999-05-15       Impact factor: 11.361

4.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

Authors:  Vassilis G Gorgoulis; Leandros-Vassilios F Vassiliou; Panagiotis Karakaidos; Panayotis Zacharatos; Athanassios Kotsinas; Triantafillos Liloglou; Monica Venere; Richard A Ditullio; Nikolaos G Kastrinakis; Brynn Levy; Dimitris Kletsas; Akihiro Yoneta; Meenhard Herlyn; Christos Kittas; Thanos D Halazonetis
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

5.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

Review 6.  Multistep skin cancer in mice as a model to study the evolution of cancer cells.

Authors:  Christopher J Kemp
Journal:  Semin Cancer Biol       Date:  2005-12       Impact factor: 15.707

7.  Dynamic change of histone H2AX phosphorylation independent of ATM and DNA-PK in mouse skin in situ.

Authors:  Manabu Koike; Minako Mashino; Jun Sugasawa; Aki Koike
Journal:  Biochem Biophys Res Commun       Date:  2007-10-01       Impact factor: 3.575

8.  Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues.

Authors:  Kay E Gurley; Christopher J Kemp
Journal:  Mol Cancer Res       Date:  2007-12       Impact factor: 5.852

9.  Atm is a negative regulator of intestinal neoplasia.

Authors:  L N Kwong; K R Weiss; K M Haigis; W F Dove
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

10.  Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis.

Authors:  Kirsteen H Maclean; Michael B Kastan; John L Cleveland
Journal:  Mol Cancer Res       Date:  2007-07       Impact factor: 5.852

View more
  8 in total

1.  Functional kinomics identifies candidate therapeutic targets in head and neck cancer.

Authors:  Russell Moser; Chang Xu; Michael Kao; James Annis; Luisa Angelica Lerma; Christopher M Schaupp; Kay E Gurley; In Sock Jang; Asel Biktasova; Wendell G Yarbrough; Adam A Margolin; Carla Grandori; Christopher J Kemp; Eduardo Méndez
Journal:  Clin Cancer Res       Date:  2014-08-15       Impact factor: 12.531

2.  Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression.

Authors:  Sharon J Pitteri; Karen S Kelly-Spratt; Kay E Gurley; Jacob Kennedy; Tina Busald Buson; Alice Chin; Hong Wang; Qing Zhang; Chee-Hong Wong; Lewis A Chodosh; Peter S Nelson; Samir M Hanash; Christopher J Kemp
Journal:  Cancer Res       Date:  2011-06-08       Impact factor: 12.701

3.  Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma.

Authors:  Russell Moser; Kay E Gurley; Olga Nikolova; Guangrong Qin; Rashmi Joshi; Eduardo Mendez; Ilya Shmulevich; Amanda Ashley; Carla Grandori; Christopher J Kemp
Journal:  Oncogene       Date:  2022-05-10       Impact factor: 8.756

4.  Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression.

Authors:  Alejo Efeyan; Matilde Murga; Barbara Martinez-Pastor; Ana Ortega-Molina; Rebeca Soria; Manuel Collado; Oscar Fernandez-Capetillo; Manuel Serrano
Journal:  PLoS One       Date:  2009-05-07       Impact factor: 3.240

5.  Doxorubicin enhances nucleosome turnover around promoters.

Authors:  Fan Yang; Christopher J Kemp; Steven Henikoff
Journal:  Curr Biol       Date:  2013-04-18       Impact factor: 10.834

6.  Loss of p53 Ser18 and Atm results in embryonic lethality without cooperation in tumorigenesis.

Authors:  Heather L Armata; Punita Shroff; David E Garlick; Krista Penta; Andrew R Tapper; Hayla K Sluss
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

Review 7.  Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets.

Authors:  Alexandros Karagiannakos; Maria Adamaki; Antonis Tsintarakis; Borek Vojtesek; Robin Fåhraeus; Vassilis Zoumpourlis; Konstantinos Karakostis
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

8.  RMP/URI inhibits both intrinsic and extrinsic apoptosis through different signaling pathways.

Authors:  Yuan Ji; Jian Shen; Min Li; Xiaoxiao Zhu; Yanyan Wang; Jiazheng Ding; Shunyao Jiang; Linqi Chen; Wenxiang Wei
Journal:  Int J Biol Sci       Date:  2019-10-15       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.